Fennec Pharmaceuticals Inc. reported its financial results for the first quarter ended March 31, 2025. The company achieved total net revenues of $8.8 million, marking an 18% increase compared to the same period in 2024, where revenues stood at $7.4 million. This growth was driven by an increase in PEDMARK product sales, particularly across new accounts in the adolescent and young adult $(AYA)$ population. Significantly, the company's refined and targeted sales strategy, coupled with enhanced patient support services through the revamped Fennec HEARS™ program, contributed to this positive momentum. Additionally, PEDMARQSI is now commercially available in Germany and the United Kingdom, expanding Fennec Pharmaceuticals' market reach. The company's operating expenses reflected a decrease in the cost of products sold, which was $373,000 compared to $550,000 in the previous year. Research and development expenses increased slightly to $94,000 from $3,000 in the first quarter of 2024. Fennec Pharmaceuticals continues to participate in key investor conferences to engage with stakeholders and discuss its business strategies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.